ArticlePloS one2025
Exploring the impact of opioid use on outcomes in allogeneic hematopoietic stem cell transplantation.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHematological malignancies and allogeneic hematopoietic cell transplantation (alloHCT) often necessitate the use of opioids due to significant pain. This study aimed to investigate the impact of opioid use on the clinical outcomes of patients undergoing alloHCT.
methodsA retrospective cohort study was conducted by merging data from our local transplant database with anonymized pharmacy records obtained from the Institute for Clinical Evaluative Sciences (ICES). We analyzed 681 patients who underwent alloHCT at Princess Margaret Cancer Centre between January 2010 and December 2019. Patients who initiated opioid use within one-year post-alloHCT and had opioid prescriptions for more than 30 days were categorized as intense opioid users (IOU). Additionally, patients who started opioids before or within one-year post-alloHCT and had opioid prescriptions for less than 30 days but died while on opioids were also classified as IOU. The analytical code used for the analysis is available in the Supporting Information file.
resultsAmong the 681 patients, 51 were identified as IOU. The two-year overall survival (OS) was significantly lower in the IOU group, with 29.4% survival compared to 53% in non-IOU (HR 1.77, 95% CI 1.26-2.48, p = 0.0008). Multivariate analysis indicated that IOU status was associated with a 2.32 times higher instantaneous rate of death compared to non-IOU (HR 2.32, 95% CI 1.5-3.5, p = 0.002). The median time for relapse was 147 days in the IOU group (range 52-393) and 209 day for non-IOU (range 96-1793), p = 0.0082. Furthermore, the relapse rate at two years was notably higher in the IOU group (31.4% vs. 16.4%, p = 0.0049). The analysis of factors independently associated with relapse-free survival (LFS) showed that IOU status, age, donor type, and cytogenetic risk were significant predictors. At two years, relapse-free survival was 29.4% in the IOU group compared to 52.5% in the non-IOU group (p < 0.001).
conclusionsIn our study, we found a correlation between intense opioid use in alloHCT patients and worse overall survival, particularly concerning higher relapse rates. These findings highlight the need for further research into pain management strategies to improve outcomes and reduce potential toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.